The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law Orthopedic Use of BPC 157 Sports Med Review Peptides Lack Reliable Safety Information, Watchdog Warns Compounded "semaglutide" is not FDA approved semaglutide.com Mitigating Risks of Compounded Drugs Through Surveillance FDA